Barclays
LYEL icon

Barclays’s Lyell Immunopharma LYEL Stock Holding History

Barclays’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.2K Buy
4,715
+3,044
+182% +$55.1K ﹤0.01% 4222
2026
Q1 		$33.5K Sell
1,671
-14,296
-90% -$334K ﹤0.01% 4445
2025
Q4 		$491K Buy
15,967
+14,775
+1,240% +$331K ﹤0.01% 3854
2025
Q3 		$19.4K Buy
1,192
+37
+3% +$423 ﹤0.01% 4938
2025
Q2 		$10.2K Sell
1,155
-8,018
-87% -$73.1K ﹤0.01% 4913
2025
Q1 		$98.7K Sell
9,173
-3,746
-29% -$45.9K ﹤0.01% 4415
2024
Q4 		$165K Buy
12,919
+888
+7% +$17.6K ﹤0.01% 4391
2024
Q3 		$332K Buy
12,031
+9,116
+313% +$268K ﹤0.01% 4025
2024
Q2 		$84.5K Sell
2,915
-4,412
-60% -$210K ﹤0.01% 3985
2024
Q1 		$327K Sell
7,327
-5,827
-44% -$250K ﹤0.01% 3845
2023
Q4 		$510K Buy
13,154
+892
+7% +$32.1K ﹤0.01% 3859
2023
Q3 		$361K Buy
12,262
+2,349
+24% +$112K ﹤0.01% 2986
2023
Q2 		$630K Sell
9,913
-2,350
-19% -$130K ﹤0.01% 2605
2023
Q1 		$579K Sell
12,263
-4,507
-27% -$241K ﹤0.01% 3163
2022
Q4 		$1.16M Buy
16,770
+10,035
+149% +$997K ﹤0.01% 2681
2022
Q3 		$988K Buy
6,735
+6,301
+1,452% +$853K ﹤0.01% 2244
2022
Q2 		$57K Sell
434
-1,198
-73% -$122K ﹤0.01% 3988
2022
Q1 		$164K Buy
+1,632
New +$198K ﹤0.01% 3541

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Barclays's LYEL Position: Q2 2026 in Review

Barclays increased its Lyell Immunopharma (LYEL) stake by 182% in Q2 2026, buying an estimated $55.1K and bringing the position to 4,715 shares worth $66.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4222.

Barclays first reported a position in LYEL in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.16M in Q4 2022. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Barclays held 4,715 shares of Lyell Immunopharma worth $66.2K as of Q2 2026.
  • Barclays bought 3,044 Lyell Immunopharma shares in Q2 2026, an estimated $55.1K.
  • Lyell Immunopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4222 holding.
  • Barclays first reported a position in Lyell Immunopharma in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Lyell Immunopharma position peaked at $1.16M in Q4 2022.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.